脑脊液途径给药神经修复治疗的中国专家共识(2022版)  

Chinese expert consensus on neurorestorative therapy with cerebrospinal fluid administration(2022)

作　　者：广东省医师协会神经修复专业医师分会 北京医师协会神经修复学专家委员会 脑脊液途径给药神经修复治疗全国协作组 陈琳 张志强 郭俭 何超 黄方杰[6] 黄红云[7] 焦红亮[8] 刘晶[9] 唐洲平[10] 王闻雅 王莹[12] 向光红 杨波[8] 张萍[10] 赵建华 无;Chen Lin;Zhang Zhiqiang(Professional Branch of Neurorestoratology,Guangdong Medical Doctor Association;Expert Committee of Neurorestoratology,Beijing Medical Doctor Association;National Collaborative Group for Neurorestorative Therapy of Cerebrospinal Fluid Administration;Department of Neurosurgery,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Department of Neurosurgery,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,Guangdong Province,China)

机构地区：[1]不详 [2]北京中医药大学东直门医院神经外科,北京市100700 [3]广州中医药大学第二附属医院神经外科,广东省广州市510120 [4]上海永慈康复医院神经康复科,上海市201110 [5]浙江省诸暨市人民医院神经外科,浙江省诸暨市311800 [6]清华大学玉泉医院神经内科,北京市100040 [7]北京市虹天济神经科学研究院,北京市100041 [8]郑州大学第一附属医院神经外科,河南省郑州市450000 [9]大连医科大学附属第一医院干细胞临床研究机构、神经内科,辽宁省大连市116011 [10]华中科技大学同济医学院附属同济医院神经内科,湖北省武汉市430030 [11]清华大学附属北京清华长庚医院生物治疗研究中心,北京市102218 [12]大连医科大学附属第一医院神经内科,辽宁省大连市116011 [13]湖南省第二人民医院神经内科,湖南省长沙市410007

出　　处：《中国组织工程研究》2023年第17期2780-2788,共9页Chinese Journal of Tissue Engineering Research

基　　金：中央高校基本科研业务费专项资金资助北京中医药大学新教师启动基金项目(2021-JYB-XJSJJ-063),项目负责人:陈琳;清华大学精准医学科研计划(10001020129),项目负责人:陈琳、李翀;广东省中医院第十三届朝阳人才项目(2022KT1228),项目负责人:李聪。

摘　　要：背景:目前神经修复药物的开发和给药方式仍然具有挑战性,加上神经系统受到血脑屏障和血脑脊液屏障的高度保护,限制了大多数药物的临床治疗效果。通过脑脊液途径直接给药至神经系统是重要的临床治疗策略,但目前缺少统一的临床应用标准。目的:对目前脑脊液途径给药的现状以及临床应用的适应证、具体方法和注意事项等进行说明,以期推广应用并提高临床疗效。方法:通过组织全国多个学科的有关专家研讨编写并最终完成该专家共识。结果与结论:脑脊液途径给药进行神经修复治疗具有较广泛的临床适应证和应用前景,但应用过程中仍需注意脑脊液途径给药的安全性、效率、给药复合配方组合、最大耐受剂量和充分的知情同意等。BACKGROUND:The nervous system is highly protected by the blood-brain barrier and the blood-cerebrospinal fluid barrier and the development and administration of neurorestorative drugs are still challenging.Therefore,the clinical therapeutic effects of most drugs are limited.Direct administration to the nervous system through the cerebrospinal fluid route is also an important clinical treatment strategy,but there is currently no unified clinical application standard.OBJECTIVE:To explain the current status of cerebrospinal fluid administration and the indications,specific methods and precautions in clinical practice,thereby popularizing the application and improving the clinical efficacy.METHODS:The Expert Committee of Neurorestoratology of Beijing Medical Doctor Association and the Professional Branch of Neurorestoratology of Guangdong Medical Doctor Association organized and compiled this expert consensus by organizing relevant expert seminars from various disciplines across the country.RESULTS AND CONCLUSION:Direct administration to the nervous system through the cerebrospinal fluid route for neurorestorative therapy has a wide range of clinical indications and application prospects.However,attention should be paid to the safety and efficiency of cerebrospinal fluid administration,the combination of compound formulations,the maximum tolerated dose and full informed consent during the application process.

关 键 词：脑脊液途径 神经修复 血脑屏障 神经营养 神经系统疾病 

分 类 号：R459.9[医药卫生—治疗学] R318[医药卫生—临床医学] R619